Chao-Hua Chiu, MD

Pulmonary Medicine

• Cancer biology
• Chemotherapy, targeted therapy, and immunology in lung cancer
• Lung cancer screening
• English
• Chinese

 

PROFESSIONAL EDUCATION：

• M.D. Taipei Medical University, Taipei, Taiwan.

 

ADMINSTRATIVE APPOINTMENTS：

• Vice Superintendent, Taipei Cancer Center, Taipei Medical University
• Attending physician, Department of Internal Medicine, Taipei Medical University Hospital
• Attending physician, Department of Internal Medicine, Taipei Medical University Hospital

 

PUBLICATIONS：

• Yang SC, Yeh YC, Chen YL, Chiu CH. Economic analysis of exclusionary EGFR test versus up-front NGS for lung adenocarcinoma in high EGFR mutation prevalence areas. J Natl Compr Canc Netw. 2022 Apr 6:1-9. Online ahead of print. (Corresponding author) {SCI}
• Chiang CL, Shen CI, Huang HC, Chang HJ, Huang YT, Chiu CH. Cytology–based specimen triage for epidermal growth factor receptor mutation testing of malignant pleural effusions in non-small cell lung cancer. Front Oncol. 2022 Jan 24;12:810124. (Corresponding author) {SCI}
• Chiang CL, Huang HC, Luo YH, Chiu CH. Cerebrospinal fluid as a medium of liquid biopsy in the management of patients with non-small-cell lung cancer having central nervous system metastasis. Front Biosci (Landmark Ed). 2021 Dec 30;26(12):1679-1688. (Corresponding author) {SCI}
• Chang CJ, Shen CI, Wu CL, Chiu CH. Pneumatosis intestinalis induced by targeted therapy. Postgrad Med J. 2022 Jan;98(1155):10. (Corresponding author) {SCI}
• Lin YT, Chiang CL, Hung JY, Lee MH, Su WC, Wu SY, Wei YF, Lee KY, Tseng YH, Su J, Chung HP, Lin CB, Ku WH, Chiang TS, Chiu CH, Shih JY. Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing. Eur J Cancer. 2021 Aug 12;156:1-11. (Co-corresponding author) {SCI}
• Chiang CL, Lee CC, Huang HC, Wu CH, Yeh YC, Shen CI, Luo YH, Shiao TH, Chang HJ, Huang YT, Chen YM, Chou TY, Chiu CH. Utility of Cerebrospinal Fluid Cell-Free DNA in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer with Leptomeningeal Metastasis. Target Oncol. 2021 Mar;16(2):207-214. (Corresponding author) {SCI}
• Chiang CL, Huang HC, Shen CI, Luo YH, Chen YM, Chiu CH. Post-Progression Survival in Secondary EGFR T790M-Mutated Non-Small-Cell Lung Cancer Patients With and Without Osimertinib After Failure of a Previous EGFR TKI. Target Oncol. 2020 Aug;15(4):503-512. (Corresponding author) {SCI}
• Chiang CL, Yeh YC, Chou TY, Chiu CH. Squamous cell carcinoma transformation after acquired resistance to osimertinib in a patient with lung adenocarcinoma harboring uncommon EGFR mutation. J Formos Med Assoc. 2020 Sep;119(9):1439-1441. (Corresponding author) {SCI}
• Shen CI, Ho HL, Yeh YC, Chiu CH, Chou TY. Epidermal growth factor receptor mutations in non-small cell lung cancer undetected by high-sensitivity allele-specific real-time polymerase chain reaction-based assays. J Chin Med Assoc. 2020 Apr;83(4):345-349. (Corresponding author) {SCI}
• Shen CI, Huang HC, Chiang CL, Luo YH, Shiao TH, Chiu CH. Effects of different brain surveillance strategies on outcomes for patients with EGFR-mutant metastatic lung adenocarcinoma under targeted therapy. Lung Cancer. 2019 Dec;138:52-57. (Corresponding author) {SCI}
• Huang HC, Su WJ, Chiang CL, Feng JY, Huang HY, Lin CH, Lin SH, Cheng CY, Chiu CH. The predictive value of the interferon-γ release assay for chemotherapy responses in patients with advanced non-small-cell lung cancer. Lung Cancer. 2018 Jan;115:64-70. (Corresponding author) {SCI}
• Chiang CL, Wang LC, Ho HL, Tsai CM, Yeh YC, Hsu WH, Chou TY, Chiu CH, Wu YC. Effect of postoperative systemic therapy on pulmonary adenocarcinoma with unexpected pleural spread detected during thoracotomy or thoracoscopy. Oncotarget. 2017 Dec 26;9(4):5435-5444. (Corresponding author) {SCI}
• Shen CI, Huang HC, Yeh YC, Chiu CH. Impending myxedema coma as the initial presentation of lung cancer. J Formos Med Assoc. 2017 Jun;116(6):488-489. (Corresponding author) {SCI}
• Chiang CL, Chen YW, Wu MH, Huang HC, Tsai CM, Chiu CH. Radiation recall pneumonitis induced by epidermal growth factor receptor-tyrosine kinase inhibitor in patients with advanced nonsmall-cell lung cancer. J Chin Med Assoc. 2016 May;79(5):248-55. (Corresponding author) {SCI}
• Chiu CH, Yang CT, Shih JY, Huang MS, Su WC, Lai RS, Wang CC, Hsiao SH, Lin YC, Ho CL, Hsia TC, Wu MF, Lai CL, Lee KY, Lin CB, Yeh DYW, Chuang CY, Chang FK, Tsai CM, Perng RP, Yang JCH. Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced lung adenocarcinomas with G719X/L861Q/S768I mutations. J Thorac Oncol. 2015 May;10(5):793-9. (First and corresponding author) {SCI}
• Chiu CH, Ho HL, Doong H, Yeh YC, Chen MY, Chou TY, Tsai CM. MLH1 V384D polymorphism associates with poor response to EGFR tyrosine kinase inhibitors in patients with EGFR L858R-positive lung adenocarcinoma. Oncotarget. 2015 Apr 10;6(10):8407-17 (First author) {SCI}
• Chiu CH, Chou TY, Chiang CL, Tsai CM. Should EGFR mutations be tested in advanced lung squamous cell carcinomas to guide frontline treatment? Cancer Chemother Pharmacol. 2014 Oct;74(4):661-5. (First author) {SCI}
• Chiu CH, Ho HL, Chiang CL, Lin SF, Ma HH, Chuang YT, Lin KY, Tsai CM, Chou TY. Clinical characteristics and treatment outcomes of lung adenocarcinomas with discrepant EGFR mutation testing results derived from PCR-direct sequencing and real-time PCR-based assays. J Thorac Oncol. 2014 Jan;9(1):91-6. (First author) {SCI}
• Huang HC, Hang JF, Wu MH, Chou TY, Chiu CH. Lung adenocarcinoma with ipsilateral breast metastasis: a simple coincidence? J Thorac Oncol. 2013 Jul;8(7):974-9. (Corresponding author) {SCI}
• Chiang CL, Tsai CM, Chou TY, Chen YM, Lai SL, Shih JF, Chiu CH, Lee YC. Erlotinib in patients with advanced lung squamous cell carcinoma. Cancer Chemother Pharmacol. 2013 Jan;71(1):203-8. (Corresponding author) {SCI}
• Chang FK, Lee YC, Chiu CH. Hyponatremia in patients with cardiac tamponade. J Chin Med Assoc. 2012 Oct;75(10):509-12 (Corresponding author) {SCI}
• Chiu CH, Yeh YC, Lin KH, Wu YC, Lee YC, Chou TY, Tsai CM. Histological subtypes of lung adenocarcinoma have differential 18F-fluorodeoxyglucose uptakes on the positron emission tomography/computed tomography scan. J Thorac Oncol. 2011 Oct;6(10):1697-703. (First author) {SCI}
• Chiu CH, Shih YN, Tsai CM, Liou JL, Chen YM, Perng RP. Serum tumor markers as predictors for survival in advanced non-small cell lung cancer patients treated with gefitinib. Lung Cancer. 2007 Aug;57(2):213-21. (First author) {SCI}
• Perng RP, Chen CY, Chang GC, Hsia TC, Hsu NY, Tsai YH, Tsai CM, Yang CH, Chen YM, Yu CJ, Lee JJ, Hsu HS, Yu CT, Kao EL, Chiu CH. Revisit of 1997 TNM staging system--survival analysis of 1112 lung cancer patients in Taiwan. Jpn J Clin Oncol. 2007 Jan;37(1):9-15. (Corresponding author) {SCI}
• Liu KT, Wu MH, Chiu CH, Tung SM, Wu YJ, Chang SC. Idiopathic acute eosinophilic pneumonia. J Chin Med Assoc. 2006 Jul;69(7):330-3. (Corresponding author)
• Chou TY, Chiu CH, Li LH, Hsiao CY, Tzen CY, Chang KT, Chen YM, Perng RP, Tsai SF, Tsai CM. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. Clin Cancer Res. 2005 May 15;11(10):3750-7. (Co-first author) {SCI}
• Chiu CH, Tsai CM, Chen YM, Chiang SC, Liou JL, Perng RP. Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity. Lung Cancer. 2005 Jan;47(1):129-38. (First author) {SCI}
• Chiu CH, Chern MS, Wu MH, Hsu WH, Wu YC, Huang MH, Chang SC. Usefulness of low-dose spiral CT of the chest in regular follow-up of postoperative non-small cell lung cancer patients: Preliminary report. J Thorac Cardiovasc Surg. 2003 Jun;125(6):1300-5. (First author) {SCI}